Alpha memo: resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Tighten the abstract and one-sentence alpha to avoid implying that Receipt 1 established a positive mechanistic/rodent signal — reframe as 'a rat protocol was designed to evaluate whether resveratrol modulates exercise-induced inflammation, while a small RCT in older men suggests it may blunt training-induced gains.'
2. Note in the Caveats section that Receipt 2 is a 2013 FASEB Journal conference supplement abstract rather than a full primary research article, which limits the strength of the human evidence.
3. Specify a numerical threshold for the 'sufficiently powered' falsifier RCT (e.g., n ≥ 27 aged men with comparable design).

Major issues

• Receipt 1 is a 2019 rat protocol (n=64 Wistar) framed in the memo as if it produced mechanistic/rodent signals suggesting resveratrol would aid exercise-related inflammation, but the bundle excerpt indicates it is an evaluation of effects on inflammation-related factors with resveratrol framed as an antioxidant. The memo overstates the rat 'signal' — the source is a planned evaluation, not a confirmed mechanistic result, and the memo itself acknowledges this in caveats but the abstract and one-sentence alpha still imply a prior positive mechanistic expectation that is not well-supported by the receipt.

Minor issues

• The title uses 'cross-context evidence signal' which is appropriate hedging, but the abstract leans slightly toward overstating the rat side as a prior mechanistic expectation given the source is a protocol/evaluation paper.
• Receipt 2 is a 2013 FASEB conference abstract (supplement 1143.7), not a full peer-reviewed primary article; this should be noted for the reader as it affects weight of evidence.
• The falsifier section is strong but could specify what 'sufficiently powered' means (e.g., n comparable to or larger than the original 27).

Reviewer note

This alpha memo makes a single bounded signal reasonably clear: resveratrol, expected on mechanistic/rodist grounds to aid exercise-related inflammation, may in fact blunt aerobic and vascular training adaptations in older men, producing a heterogeneous cross-context pattern. The two-receipt bundle is appropriate in size for a narrow memo, and the caveats section is unusually strong — it explicitly flags species, dose, modality, duration, and baseline differences and identifies a clean falsifier (a powered replication RCT in aged men). Source grounding is solid: the bundle excerpts support the core claims about the 2019 rat evaluation and the 2013 RCT design and direction of effect, and exact statistics are not cross-checkable but not internally contradictory. The main issue is a mild overclaim on Receipt 1. The memo's abstract and one-sentence alpha frame the rat work as a prior 'mechanistic and rodent signal' that suggested benefit, but the bundle makes clear it is a protocol/aimed-to-evaluate study, and the memo's own caveats acknowledge this. This creates a small but real tension between the headline framing and the actual receipt. Additionally, Receipt 2 is a FASEB conference supplement abstract rather than a full primary article, which the memo does not flag. Both issues are fixable with bounded edits — tightening the abstract's framing of the rat evidence and adding a one-line note on the conference-abstract status of Receipt 2. The memo's overall structure, honesty about heterogeneity, and falsifier specification are strong points. Recommendation: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis